View Post The ASSURE Study: HIV-1 Suppression Is Maintained with Bone and Renal Biomarker Improvement 48 Weeks after Ritonavir Discontinuation and Randomized Switch to Abacavir/Lamivudine + Atazanavir. HIV Medicine, 17(2): 106-117. In by AHFFebruary 1, 2016
View Post Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. The New England Journal of Medicine, 359: 1429-1441. In by AHFOctober 1, 2008
View Post Efficacy and Safety of Once-Daily Darunavir/Ritonavir Versus Lopinavir/Ritonavir in Treatment-Naive HIV-1-Infected Patients at Week 48. AIDS, 22(12): 1389-1397. In by AHFMarch 1, 2008
View Post Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients. Journal of Acquired Immune Deficiency Syndromes, 43(1): 1-5. In by AHFSeptember 1, 2006
